ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!CLSD Company Profile and Key Details
Clearside Biomedical, Inc.
CLSD Stock Price Chart
Stock Price Today
Clearside Biomedical, Inc. (CLSD) stock declined over -7.77%, trading at $0.95 on NASDAQ, down from the previous close of $1.03. The stock opened at $1.02, fluctuating between $0.95 and $1.02 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Company Information
| Employees | 30 |
| Beta | 2.22 |
| Sales or Revenue | $8.23M |
| 5Y Sales Change% | 135.346% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Clearside Biomedical, Inc. (NASDAQ: CLSD) stock price is $0.95 in the last trading session. During the trading session, CLSD stock reached the peak price of $1.02 while $0.95 was the lowest point it dropped to. The percentage change in CLSD stock occurred in the recent session was -7.77% while the dollar amount for the price change in CLSD stock was -$0.08.
The NASDAQ listed CLSD is part of Biotechnology industry that operates in the broader Healthcare sector. Clearside Biomedical, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Thomas A. Ciulla M.B.A., M.D.
Chief Medical Officer & Chief Devel. Officer
Mr. Rick McElheny
Vice President of Corporation Devel.
Mr. Leslie B. Zacks
Sec.
Ms. Jenny R. Kobin
Head of Investor Relations
Mr. Rafael V. Andino
Senior Vice President of Engineering & Manufacturing
Mr. Charles A. Deignan
Chief Financial Officer
Ms. Susan L. Coultas Ph.D.
Chief Clinical Officer
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Pres, Chief Executive Officer & Director
CLSD's closing price is 18.6% higher than its 52-week low of $0.80 where as its distance from 52-week high of $2.12 is -55.19%.
Number of CLSD employees currently stands at 30.
Official Website of CLSD is: https://www.clearsidebio.com
CLSD could be contacted at phone 678 270 3631 and can also be accessed through its website. CLSD operates from 900 North Point Parkway, Alpharetta, GA 30005, United States.
CLSD stock volume for the day was 224.27K shares. The average number of CLSD shares traded daily for last 3 months was 245.67K.
The market value of CLSD currently stands at $72.05M with its latest stock price at $0.95 and 75.84M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com